Sisu Global is a 2022 TiE50 Winner! TiE50 is TiE Silicon Valley’s premier annual awards program, contested by thousands of early to mid-stage startups worldwide.
“Sisu Global is grateful to be a part of the TiE50 community this year. We are looking forward to the opportunity of working together and our expansion into India.” President & Co-founder, Gillian Henker
Visit the link in the comments below to learn more about TiE50.
The National Institutes of Health (NIH) is a critical pillar of the U.S. public health system and a beacon of guidance for healthcare best practices across the globe. This has never been more evident than during the COVID-19 crisis.
A lesser-known NIH facet is its long and productive history of technology transfer success.
Linshom is First to Deliver an Operating-Room-Quality Respiratory Profile to Patient Bedside for Continuous, Predictive Respiratory Monitoring (CPRM)
Baltimore, Md. (April 27, 2022) – Linshom (“to breathe”), a Maryland-based startup developing a respiratory monitoring system, closed a $1.5 million Series A funding round with investment from the Maryland Momentum Fund and current investors.
The Linshom Respiratory Sensor and Monitor is the first predictive, continuous respiratory monitoring system able to practically reach the patients’ bedside. Severe respiratory events can begin to cause brain damage only three minutes after breathing ceases. While critical care patients are continuously monitored for respiratory function, patients on general care floors are not monitored as closely, but are still at risk for serious respiratory complications. The Linshom Respiratory System bridges that gap, helping clinicians respond more quickly to severe respiratory-related events.
May 16, 2022 (Columbia, Md.)—The Maryland Stem Cell Research Commission announced it will grant $7,067,409 in award funding to innovative research that will strengthen and advance stem cell treatments and technologies in Maryland. Awardees submitted proposals to the Commission in response to its Request for Applications (RFAs) for its second round of funding cycle in 2022.
Recipients include 24 scientists accelerating research at Johns Hopkins University, Britecyte, Inc., RenOVAte Biosciences, Inc., RoosterBio, Inc., and the University of Maryland, Baltimore.
What is a pre-IND? Why have a pre-IND? What goes into preparing for a pre-IND? And, what documents are required? All of these questions and more will be answered in this webinar presented by Dr. Carmella Moody, a regulatory affairs specialist at RTI International. Dr. Carmella Moody brings her expertise in regulatory affairs and the development of small molecules to the Catalyze program, where she serves as a technical project lead. In this 1-hour webinar, Dr. Moody will explain the process of preparing and approaching an effective pre-IND meeting, but also what to expect from FDA feedback and how to incorporate it into your project to ultimately save time and money.
Vita Therapeutics CEO & Co-founder Douglas Falk chats with Rich Bendis to discuss his career, their platforms, and moving into the University of Maryland BioPark.
Listen now on Apple https://apple.co/3wwzX8N, Google https://bit.ly/3wxbQag, Spotify https://spoti.fi/3sCZH2t, Amazon https://amzn.to/3G3DLDb, and TuneIn https://bit.ly/3FStLfF.
Douglas Falk, MS is the Co-founder and CEO of Vita Therapeutics, a biotechnology company generating state-of-the-art cellular therapeutics for the treatment of muscular dystrophies and solid tumors. He has experience in healthcare equity research investing as a former Principal at Brown Advisory. He has led direct investment into more than 30 biotechnology companies and is a Board Member of Johns Hopkins University’s Biotech Investment Group.
GAITHERSBURG, Md., May 16, 2022 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into a definitive agreement with Chimerix, Inc. (NASDAQ: CMRX), to acquire Chimerix’s exclusive worldwide rights to TEMBEXA® (brincidofovir), the first antiviral approved by the U.S. Food and Drug Administration (FDA) for all age groups for the treatment of smallpox. TEMBEXA was approved in June 2021 and is indicated for the treatment of human smallpox disease in adult and pediatric patients, including neonates.
ROCKVILLE, Md., May 16, 2022 /PRNewswire/ — Emmes, a global, full-service clinical research organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced that it is providing data, statistical analysis, and project management support for new research that will test the Moderna mRNA vaccine at more than 50 sites in South and East Africa.
The clinical trial, which will include about 15,600 participants, seeks to better understand infection and disease in immunocompromised populations in order to prevent severe COVID-19 and chronic SARS-CoV-2 infections and minimize the risk of transmission. The study will also address the COVID-19 mRNA vaccine’s resistance to the variants that have been detected in South Africa and surrounding countries.
No question about it—2021 was a banner year for initial public offerings.
Nasdaq data indicates 1,033 IPOs last year, more than double 2020’s 471. As we move further into 2022, the market has slowed considerably. In the first quarter, only 95 companies filed initial public offerings as opposed to 419 in the first quarter of 2021.
Image: https://www.crainsnewyork.com/
MIMETAS, a global leader in Organ-on-a-Chip models and technology and headquartered in the Netherlands (Europe), announces that it has expanded its license to the HUB Organoid Technology to include all organs. The license covers organoid technology developed by Professor Hans Clevers, a pioneer in adult stem cells.
